Marc Rendell, MD is conducting a research study at the Creighton Diabetes Center

This study is comparing a new insulin lispro with a currently marketed insulin lispro (Humalog) in patients with type 1 diabetes who are also using insulin glargine.

We are looking for people who meet the following criteria:

1. People who have been diagnosed with type 1 diabetes at least 12 months and have been using insulin glargine and Humalog or Novolq/NovoRapid for at least 6 months.
2. People who are not using an insulin pump.

If you are interested in knowing more about this research study, please call (or e-mail):

Merideth Dunn
dunnwall@creighton.edu
(402) 280-4379

Stipend Available:

☐ Yes          ☐ No

To find out more information about being a research participant, the benefits of participating in research at Creighton University, and your rights as a research participant, please visit Creighton’s Research Participant Information web page at [http://www.creighton.edu/researchcompliance/humanresearchprotectionprogram/researchparticipantinformation/index.php](http://www.creighton.edu/researchcompliance/humanresearchprotectionprogram/researchparticipantinformation/index.php).